Repurposing FDA approved drugs as possible anti-SARS-CoV-2 medications using ligand-based computational approaches: sum of ranking difference-based model selection

The worldwide burden of coronavirus disease 2019 (COVID-19) is still unremittingly prevailing, with more than 440 million infections and over 5.9 million deaths documented so far since the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic. The non-availability of treatment furthe...

Descripción completa

Detalles Bibliográficos
Autores principales: De, Priyanka, Kumar, Vinay, Kar, Supratik, Roy, Kunal, Leszczynski, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171098/
https://www.ncbi.nlm.nih.gov/pubmed/35692512
http://dx.doi.org/10.1007/s11224-022-01975-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171098/
https://www.ncbi.nlm.nih.gov/pubmed/35692512
http://dx.doi.org/10.1007/s11224-022-01975-3

Ejemplares similares